» Articles » PMID: 27460076

The Inflammatory Microenvironment in Epithelial Ovarian Cancer: a Role for TLR4 and MyD88 and Related Proteins

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2016 Jul 28
PMID 27460076
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7-1.8], both strong HR 2.1 [95 % CI 1.1-3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

Citing Articles

Targeting protein tyrosine phosphatase non-receptor type 6 (PTPN6) as a therapeutic strategy in acute myeloid leukemia.

Wang X, Li Z, Shen J, Liu L Cell Biol Toxicol. 2024; 41(1):11.

PMID: 39707066 PMC: 11662038. DOI: 10.1007/s10565-024-09965-3.


The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.

Kim K, Khazan N, McDowell J, Snyder C, Miller J, Singh R PLoS One. 2024; 19(12):e0314564.

PMID: 39621651 PMC: 11611113. DOI: 10.1371/journal.pone.0314564.


MiR-5195-3p predicts clinical prognosis and represses colorectal cancer progression by targeting TLR4/MyD88 signaling.

Lv Y, Guo S, Jin L, Wang K, Li Y, Li H Cell Div. 2024; 19(1):29.

PMID: 39390599 PMC: 11468180. DOI: 10.1186/s13008-024-00133-x.


High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Wilczynski J, Paradowska E, Wilczynski M Biomedicines. 2024; 12(1).

PMID: 38275400 PMC: 10813374. DOI: 10.3390/biomedicines12010229.


OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer.

Yu Z, Ouyang L Discov Oncol. 2023; 14(1):159.

PMID: 37642735 PMC: 10465422. DOI: 10.1007/s12672-023-00778-0.


References
1.
Szajnik M, Szczepanski M, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E . TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009; 28(49):4353-63. PMC: 2794996. DOI: 10.1038/onc.2009.289. View

2.
De Nardo D . Toll-like receptors: Activation, signalling and transcriptional modulation. Cytokine. 2015; 74(2):181-9. DOI: 10.1016/j.cyto.2015.02.025. View

3.
Guo R, Qiao Y, Zhou Y, Li L, Shi H, Chen K . Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int. 2008; 58(12):749-56. DOI: 10.1111/j.1440-1827.2008.02306.x. View

4.
Kim K, Jo M, Suh D, Yoon M, Shin D, Lee J . Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol. 2012; 10:193. PMC: 3539930. DOI: 10.1186/1477-7819-10-193. View

5.
Kobel M, Kalloger S, Lee S, Duggan M, Kelemen L, Prentice L . Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 2013; 22(10):1677-86. PMC: 3955399. DOI: 10.1158/1055-9965.EPI-13-0391. View